Business Context and Reporting Period
This Form 8-K reports on the 2024 Annual Meeting of Stockholders held by Salarius Pharmaceuticals, Inc. on December 20, 2024. The filing details the voting results for three proposals submitted to security holders. As of the record date (October 25, 2024), there were 1,441,157 shares of common stock outstanding, with 572,540 shares (39.7%) present or represented by proxy, constituting a quorum.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes rather than financial performance.
Material Changes and Voting Results
Stockholders voted on the following proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Re-elected two Class III directors to serve until 2027.
- Tess Burleson: 141,974 votes For; 12,711 votes Against; 2,127 Abstentions.
- Paul Lammers: 145,485 votes For; 9,196 votes Against; 2,131 Abstentions.
- Proposal 2 (Executive Compensation): Approved, on a non-binding advisory basis, the compensation of named executive officers.
- 135,949 votes For; 18,637 votes Against; 2,226 Abstentions.
- Proposal 3 (Auditor Ratification): Ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- 496,239 votes For; 59,576 votes Against; 16,725 Abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Important Facts for Investors to Verify
- Confirmation that the re-elected directors (Tess Burleson and Paul Lammers) will serve until the 2027 annual meeting.
- Verification of the non-binding advisory vote outcome on executive compensation, noting the significant number of votes against (18,637).
- Confirmation that Ernst & Young LLP has been ratified as the auditor for the fiscal year ending December 31, 2024.
- Review of the full proxy statement for details on executive compensation and director biographies referenced in the voting proposals.